Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 6/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.56 |
| ▸ | CA2 | P00918 | 6/20 | 0.56 |
| ▸ | CA9 | Q16790 | 6/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21596987 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL6449941 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL7292779 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL17286185 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL1041731 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL19460948 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL26634879 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL18604607 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL229087 | 0.98 | TDP1 (0.68) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL7434 | 0.92 | TDP1 (0.65) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102161688-A | Cholesterol-structure-fragment-containing biocompatible synthesis liposomes as well as preparation method and application thereof | SHANGHAI INST ORGANIC CHEM | 2011-08-24 | — | — | CN | claimed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12582641-B2 | Sulfur-containing compound based on glutarimide skeleton and application thereof | SHANGHAITECH UNIVERSITY (CN) | 2026-03-24 | — | — | US | disclosed |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12564638-B2 | EGFR protein degradant and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2026-03-03 | — | — | US | disclosed |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12517130-B2 | Isoindoline derivatives which bind to an ATP binding site | Neophore Limited (GB) | 2026-01-06 | — | — | US | disclosed |
| US-20250361401-A1 | REACTIVE DYES | ALCON INC (CH) | 2025-11-27 | — | — | US | disclosed |
| WO-2006065218-A1 | NOVEL MOLECULAR PROBES | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | WYETH (US) | 2003-06-12 | — | — | US | disclosed |
| US-6429214-B1 | INHIBITORS OF BONE RESORPTION | WYETH | 2002-08-06 | — | — | US | disclosed |
| EP-1198231-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE(ALPHA)V(BETA)3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001007036-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-0528586-B1 | Inhibiting osteoclast-mediated bone resorption using aminoalkyl-substituted phenyl derivatives | MERCK & CO INC (US) | 1995-02-22 | — | — | EP | disclosed |
| US-5217994-A | METHOD OF INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION BY ADMINISTRATION OF AMINOALKYL-SUBSTITUTED PHENYL DERIVATIVES | MERCK & CO., INC. (US) | 1993-06-08 | — | — | US | disclosed |
| US-5204350-A | Treating osteoporosis | MERCK & CO., INC. (US) | 1993-04-20 | — | — | US | disclosed |
| EP-0528587-A1 | Inhibiting osteoclast-mediated bone resorption using substituted phenyl derivatives | MERCK & CO. INC. (US) | 1993-02-24 | — | — | EP | disclosed |
| EP-0528586-A1 | Inhibiting osteoclast-mediated bone resorption using aminoalkyl-substituted phenyl derivatives | MERCK & CO. INC. (US) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582641-B2 | Sulfur-containing compound based on glutarimide skeleton and application thereof | SUCNR1, SRD5A1, GLS | TDP1 2396/4885MAOA 3009/4885MAOB 2365/4885 |
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | ITGAV, ITGB2, ITGB3 | TDP1 4487/4885MAOA 2218/4885MAOB 1354/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | TDP1 3694/4885MAOA 1115/4885MAOB 1349/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | TDP1 3646/4885MAOA 1060/4885MAOB 1273/4885 |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | TDP1 3181/4885MAOA 2140/4885MAOB 2300/4885 |
| US-12564638-B2 | EGFR protein degradant and anti-tumor application thereof | EGFR, ERBB2, ERBB3 | TDP1 4066/4885MAOA 4144/4885MAOB 4103/4885 |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | CRBN, STUB1, CUL1 | TDP1 3232/4885MAOA 3986/4885MAOB 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.